APOB was also highlighted as a useful tool to predict resistance to treatment, where serum lipid levels of APOB as well as APOA1 were found to be useful in predicting the response of patients with advanced intrahepatic cholangiocarcinoma to PD-1 inhibitor treatment [143]. The gene discussed is APOB; the disease is intrahepatic cholangiocarcinoma.